![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:5906B Cambridge Antibody Tech Group PLC 4 April 2001 For Further Information Contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 David Chiswell, CEO John Aston, Finance Director Rowena Gardner, Head of Corporate Communications HCC De Facto (Europe) Tel: +44 (0) 20 7496 3300 Adam Michael David Speechly BMC Communications/The Trout Group (USA) Tel: 001 212 477 9007 Brad Miles, ext 17 (media) Brandon Lewis, ext.15 (investors) PROPOSED NASDAQ LISTING: CAT MAKES PUBLIC FILING WITH SEC Melbourn, UK Cambridge Antibody Technology (LSE : CAT) announces that it has now made a public filing with the SEC in preparation for its proposed listing of ADRs on the NASDAQ market, as previously announced. This filing follows an extensive period of consultation with the SEC. The filing of a registration statement does not guarantee that CAT's ADRs will be listed at any time or at all. Notes to Editors: Cambridge Antibody Technology (LSE: CAT) CAT is a UK biotechnology company using its proprietary technologies in human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 210 people. CAT's ordinary shares are listed on the London Stock Exchange. CAT raised #41m in its IPO in March 1997 and #93m (#89.4m net of expenses) in a secondary offering in March 2000. CAT has an advanced platform technology for rapidly isolating human monoclonal antibodies, primarily using phage display technology. CAT's library currently incorporates around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. Four human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT works in partnership with other companies at all stages of the drug discovery and development process. CAT's collaborations, past and present, include: AstraZeneca, Knoll AG, Eli Lilly, Genentech, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst and Zyomyx.
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions